Akebia Therapeutics Inc (AKBA)

05:42 AM

What analysts say about Akebia Therapeutics Inc. stockFree Consultation - Autocar Professional

05:42 AM

07:28 AM

Akebia Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com

07:28 AM

12:48 PM

Is Akebia Therapeutics Inc. a good long term investmentRemarkable growth - jammulinksnews.com

12:48 PM

Jul 22, 2025

Lobbying Update: $460,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq

Jul 22, 2025

Jul 22, 2025

What drives Akebia Therapeutics Inc. stock pricePhenomenal trading returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share - Insider Monkey

Jul 22, 2025

Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025

Jul 18, 2025

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Jul 18, 2025

Jul 16, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GATO, AKBA and LCID - ACCESS Newswire

Jul 16, 2025

Jul 16, 2025

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Jul 16, 2025

Jul 16, 2025

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 16, 2025

Jul 16, 2025

PHD inhibitors reported in Akebia Therapeutics patent - BioWorld MedTech

Jul 16, 2025

Jul 14, 2025

Transcript : Akebia Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 10 - MarketScreener

Jul 14, 2025

Jul 14, 2025

Akebia at H.C. Wainwright: Strategic Insights on Kidney Care Products By Investing.com - Investing.com Canada

Jul 14, 2025

Jul 12, 2025

Akebia Ther stock hits 52-week high at 4.08 USD - Investing.com Australia

Jul 12, 2025

Jul 11, 2025

Akebia Ther stock hits 52-week high at 4.08 USD By Investing.com - Investing.com Nigeria

Jul 11, 2025

Jul 08, 2025

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN

Jul 08, 2025

Jul 08, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

Upcoming Kidney Disease Conference: Akebia CCO to Share Latest Commercial Strategy - Stock Titan

Jul 08, 2025

Jul 07, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Jul 07, 2025

Jul 07, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 07, 2025

Jul 03, 2025

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Jul 03, 2025

Jul 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 01, 2025

Jun 30, 2025

12 Small Cap Stocks with High Upside Potential - Insider Monkey

Jun 30, 2025

Jun 27, 2025

Wall Street Nears Record Highs Amid Trade Optimism, Jobs Data, and Fiscal Policies in Focus. - AInvest

Jun 27, 2025

Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025

Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 23, 2025

Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025

Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025

Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025

Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025

Jun 13, 2025

Akebia Therapeutics expands stock incentive plan - Investing.com Australia

Jun 13, 2025